We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-12.68%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.68B
AUM Growth
-$191M
Cap. Flow
+$173M
Cap. Flow %
10.28%
Top 10 Hldgs %
55%
Holding
67
New
15
Increased
26
Reduced
11
Closed
7

Top Buys

1
ZBH icon
Zimmer Biomet
ZBH
+$53.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.7M
3
BLU
BELLUS Health Inc.
BLU
+$29.5M
4
DMTK
DermTech, Inc. Common Stock
DMTK
+$28.5M
5
PTCT icon
PTC Therapeutics
PTCT
+$22.4M

Top Sells

1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$34.1M
2
ILMN icon
Illumina
ILMN
+$30.2M
3
ARWR icon
Arrowhead Research
ARWR
+$29.7M
4
KIDS icon
OrthoPediatrics
KIDS
+$14.7M
5
MYGN icon
Myriad Genetics
MYGN
+$10.5M

Sector Composition

1 Healthcare 94.09%
2 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$376M
$193M 11.45%
16,587,491
– –
ALNY icon
2
Alnylam Pharmaceuticals
ALNY
$35.7B
$142M 8.45%
1,767,628
-430,466
-20% -$34.1M
PTCT icon
3
PTC Therapeutics
PTCT
$6.52B
$123M 7.34%
3,651,361
+514,000
+16% +$22.4M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$89.1M 5.3%
6,202,425
+50,322
+0.8% +$719K
BMY icon
5
Bristol-Myers Squibb
BMY
$124B
$79.4M 4.72%
1,565,307
+3,389
+0.2% +$159K
STOK icon
6
Stoke Therapeutics
STOK
$1.81B
$69.4M 4.13%
3,355,466
– –
MIST icon
7
Milestone Pharmaceuticals
MIST
$147M
$63.8M 3.8%
3,521,856
– –
ZBH icon
8
Zimmer Biomet
ZBH
$17.6B
$55.3M 3.29%
+415,090
New +$53.6M
MASI
9
DELISTED
Masimo
MASI
$55.2M 3.28%
371,155
-1,103
-0.3% -$168K
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.82B
$54.6M 3.24%
724,311
+120,075
+20% +$14.2M
ACHN
11
DELISTED
Achillion Pharmaceuticals
ACHN
$49.9M 2.97%
13,864,383
– –
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$46.2M 2.75%
592,776
+337,506
+132% +$31.7M
QTTB icon
13
Q32 Bio
QTTB
$255M
$44.3M 2.64%
136,082
+21,919
+19% +$7.45M
AXNX
14
DELISTED
Axonics, Inc. Common Stock
AXNX
$41.3M 2.46%
1,534,605
– –
VCEL icon
15
Vericel Corp
VCEL
$2.38B
$40.1M 2.38%
2,645,476
+38,705
+1% +$677K
ESTA icon
16
Establishment Labs
ESTA
$2.72B
$38.6M 2.29%
2,039,681
+156,501
+8% +$3.37M
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$37.8M 2.25%
725,025
+1,570
+0.2% +$83.5K
ADVM
18
DELISTED
Adverum Biotechnologies
ADVM
$34.2M 2.04%
628,100
-3,935
-0.6% -$443K
TBIO
19
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$31.2M 1.86%
3,148,628
+709,378
+29% +$6.7M
BLU
20
DELISTED
BELLUS Health Inc.
BLU
$26.9M 1.6%
+4,178,156
New +$29.5M
AGEN
21
Agenus
AGEN
$208M
$23.8M 1.41%
469,412
-44,379
-9% -$2.37M
APYX icon
22
Apyx Medical
APYX
$181M
$22.8M 1.36%
3,370,279
-29,620
-0.9% -$210K
PRQR icon
23
ProQR Therapeutics
PRQR
$241M
$21.3M 1.27%
3,700,833
-22,117
-0.6% -$177K
PODD icon
24
Insulet
PODD
$11.4B
$18.3M 1.09%
+111,232
New +$15.6M
LJPC
25
DELISTED
La Jolla Pharmaceutical Company
LJPC
$17.7M 1.06%
2,016,269
+4,929
+0.2% +$46.6K
1
2 3

Similar funds

BEI
Benjamin Edwards Inc Clayton, Missouri $10.1B AUM 14.03% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return

RTW Investments's Q3 2019 Portfolio in Review

As of Q3 2019, RTW Investments held 67 positions worth $1.68B, down 10% from $1.87B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RTW Investments deployed $173M of net new capital in Q3 2019, opening 15 new positions and adding to 26 existing holdings. Its largest new stake was Zimmer Biomet: 415,090 shares worth $55.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $34.1M trimmed.

  • RTW Investments's largest Q3 2019 buy was Zimmer Biomet: 415,090 shares worth $55.3M.
  • RTW Investments added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $31.7M increase.
  • RTW Investments's biggest Q3 2019 reduction was Alnylam Pharmaceuticals, cutting an estimated $34.1M.
  • RTW Investments fully exited Illumina in Q3 2019, selling an estimated $30.2M.
  • RTW Investments's ten largest holdings make up 55% of its $1.68B portfolio in Q3 2019.
  • RTW Investments opened 15 new positions and closed 7 in Q3 2019.
  • RTW Investments's portfolio value fell 10% quarter-over-quarter to $1.68B.

Based on RTW Investments's 13F filing for Q3 2019, filed 14 Nov 2019.